Combination Pharmacotherapy for Stopping Smoking: What Advantages Does It Offer?

Overview

Journal Drugs

Specialty Pharmacology

Date 2010 Apr 17

PMID 20394453

Citations 31

Authors

Jon O Ebbert

J Taylor Hays

Richard D Hurt

Affiliations

Soon will be listed here.

Abstract

Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.

Citing Articles

Varenicline and Nicotine Replacement Therapy for Smokers Admitted to Hospitals: A Randomized Clinical Trial.

Weeks G, Gobarani R, Abramson M, Bonevski B, Webb A, Thomas D JAMA Netw Open. 2024; 7(6):e2418120.

PMID: 38935378 PMC: 11211956. DOI: 10.1001/jamanetworkopen.2024.18120.

Clinical challenges facing patient participation in cardiac rehabilitation: cigarette smoking.

Gaalema D, Khadanga S, Pack Q Expert Rev Cardiovasc Ther. 2023; 21(11):733-745.

PMID: 37938825 PMC: 11567058. DOI: 10.1080/14779072.2023.2282026.

Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial.

Sifat M, Hebert E, Ahluwalia J, Businelle M, Waring J, Frank-Pearce S JMIR Form Res. 2023; 7:e48857.

PMID: 37889541 PMC: 10638635. DOI: 10.2196/48857.

Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.

Lindson N, Theodoulou A, Ordonez-Mena J, Fanshawe T, Sutton A, Livingstone-Banks J Cochrane Database Syst Rev. 2023; 9:CD015226.

PMID: 37696529 PMC: 10495240. DOI: 10.1002/14651858.CD015226.pub2.

Randomized clinical trial examining financial incentives for smoking cessation among mothers of young children and possible impacts on child secondhand smoke exposure.

Higgins S, Plucinski S, Orr E, Nighbor T, Coleman S, Skelly J Prev Med. 2023; 176:107651.

PMID: 37527730 PMC: 10825067. DOI: 10.1016/j.ypmed.2023.107651.

References

George T, Vessicchio J, Sacco K, Weinberger A, Dudas M, Allen T . A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2007; 63(11):1092-6. PMC: 2693008. DOI: 10.1016/j.biopsych.2007.11.002. View

Hurt R, Sachs D, Glover E, Offord K, Johnston J, DALE L . A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997; 337(17):1195-202. DOI: 10.1056/NEJM199710233371703. View

Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E . Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control. 2006; 15(3):152-9. PMC: 2564651. DOI: 10.1136/tc.2005.011551. View

Piper M, Smith S, Schlam T, Fiore M, Jorenby D, Fraser D . A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009; 66(11):1253-62. PMC: 2933113. DOI: 10.1001/archgenpsychiatry.2009.142. View

Evins A, Cather C, Culhane M, Birnbaum A, Horowitz J, Hsieh E . A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007; 27(4):380-6. DOI: 10.1097/01.jcp.0b013e3180ca86fa. View

Jorenby D, Hays J, Rigotti N, Azoulay S, Watsky E, Williams K . Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1):56-63. DOI: 10.1001/jama.296.1.56. View

Gonzales D, Rennard S, Nides M, Oncken C, Azoulay S, Billing C . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1):47-55. DOI: 10.1001/jama.296.1.47. View

Koob G . Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992; 13(5):177-84. DOI: 10.1016/0165-6147(92)90060-j. View

Cahill K, Stead L, Lancaster T . Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008; (3):CD006103. DOI: 10.1002/14651858.CD006103.pub3. View

10.

Smith S, McCarthy D, Japuntich S, Christiansen B, Piper M, Jorenby D . Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009; 169(22):2148-55. PMC: 2891174. DOI: 10.1001/archinternmed.2009.426. View

11.

Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M . Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ. 2008; 336(7655):1223-7. PMC: 2405820. DOI: 10.1136/bmj.39545.852616.BE. View

12.

Schnoll R, Patterson F, Wileyto E, Heitjan D, Shields A, Asch D . Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010; 152(3):144-51. PMC: 3782858. DOI: 10.7326/0003-4819-152-3-201002020-00005. View

13.

Hughes J, Kalman D . Do smokers with alcohol problems have more difficulty quitting?. Drug Alcohol Depend. 2005; 82(2):91-102. DOI: 10.1016/j.drugalcdep.2005.08.018. View

14.

Faessel H, Gibbs M, Clark D, Rohrbacher K, Stolar M, Burstein A . Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006; 46(12):1439-48. DOI: 10.1177/0091270006292624. View

15.

Jorenby D, Leischow S, Nides M, Rennard S, Johnston J, Hughes A . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340(9):685-91. DOI: 10.1056/NEJM199903043400903. View

16.

Ebbert J, Sood A, Hays J, Dale L, Hurt R . Treating tobacco dependence: review of the best and latest treatment options. J Thorac Oncol. 2007; 2(3):249-56. DOI: 10.1097/JTO.0b013e318031bca4. View

17.

Blondal T, Gudmundsson L, Olafsdottir I, Gustavsson G, Westin A . Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ. 1999; 318(7179):285-8. PMC: 27708. DOI: 10.1136/bmj.318.7179.285. View

18.

Ebbert J, Croghan I, Sood A, Schroeder D, Hays J, Hurt R . Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009; 11(3):234-9. DOI: 10.1093/ntr/ntn031. View

19.

Ebbert J, Burke M, Hays J, Hurt R . Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009; 11(5):572-6. DOI: 10.1093/ntr/ntp042. View

20.

Grant K, Kelley S, Smith L, Agrawal S, Meyer J, Romberger D . Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol. 2007; 41(5):381-91. PMC: 2064868. DOI: 10.1016/j.alcohol.2007.03.011. View